tbuckley/cabot-search huggingface dataset:
Entrectinib in children and young adults with solid or primary CNS tumors harboring <i>NTRK</i>, <i>ROS1</i>, or <i>ALK</i> aberrations (STARTRK-NG)
Authors: Ami V Desai, Giles W Robinson, Karen Gauvain, Ellen M Basu, Margaret E Macy, Luke Maese, Nicholas S Whipple, Amit J Sabnis, Jennifer H Foster, Suzanne Shusterman, Janet Yoon, Brian D Weiss, Mohamed S Abdelbaki, Amy E Armstrong, Thomas Cash, Christine A Pratilas, Nadège Corradini, Lynley V Marshall, Mufiza Farid-Kapadia, Saibah Chohan, Clare Devlin, Georgina Meneses-Lorente, Alison Cardenas, Katherine E Hutchinson, Guillaume Bergthold, Hubert Caron, Edna Chow Maneval, Amar Gajjar, Elizabeth Fox
Journal: Neuro-Oncology (2022)

Entrectinib is a TRKA/B/C, ROS1, ALK tyrosine kinase inhibitor approved for the treatment of adults and children aged ≥12 years with NTRK fusion-positive solid tumors and adults with ROS1 fusion-positive non–small-cell lung cancer. We report an analysis of the STARTRK-NG trial, investigating the recommended phase 2 dose (RP2D) and activity of entrectinib in pediatric patients with solid tumors including primary central nervous system tumors. STARTRK-NG (NCT02650401) is a phase 1/2 trial. Phase 1, dose-escalation of oral, once-daily entrectinib, enrolled patients aged <22 years with solid tumors with/without target NTRK1/2/3, ROS1, or ALK fusions. Phase 2, basket trial at the RP2D, enrolled patients with intracranial or extracranial solid tumors harboring target fusions or neuroblastoma. Primary endpoints: phase 1, RP2D based on toxicity; phase 2, objective response rate (ORR) in patients harboring target fusions. Safety-evaluable patients: ≥1 dose of entrectinib; response-evaluable patients: measurable/evaluable baseline disease and ≥1 dose at RP2D. At data cutoff, 43 patients, median age of 7 years, were response-evaluable. In phase 1, 4 patients experienced dose-limiting toxicities. The most common treatment-related adverse event was weight gain (48.8%). Nine patients experienced bone fractures (20.9%). In patients with fusion-positive tumors, ORR was 57.7% (95% CI 36.9-76.7), median duration of response was not reached, and median (interquartile range) duration of treatment was 10.6 months (4.2-18.4). Entrectinib resulted in rapid and durable responses in pediatric patients with solid tumors harboring NTRK1/2/3 or ROS1 fusions.
Prolonged viral shedding in severely ill patients infected with SARS-CoV-2 Delta variants: A retrospective cohort study
Authors: Yae Jee Baek, Youn-Jung Lee, Jae In Kim, Seju Lee, Jinnam Kim, Eun Hwa Lee, Ki Hyun Lee, Jung Ho Kim, Jin Young Ahn, Su Jin Jeong, Nam Su Ku, Joon-Sup Yeom, Jun Yong Choi
Journal: Journal of Infection (2022)
Clinical, immunological and genomic analysis of the post vaccinated SARS-CoV-2 infected cases with Delta derivatives from Maharashtra, India, 2021
Authors: Pragya D. Yadav, Rima R. Sahay, Sachee Agrawal, Anita Shete, Balkrishna Adsul, Srikanth Tripathy, Dimpal A. Nyayanit, Manish Manrai, Deepak Y. Patil, Sanjay Kumar, Vikas Marwah, Gajanan N. Sapkal, Jayanthi Shastri, Rajlakshmi Viswanathan, Priyanka Pandit, Yogendra Mishra, Smita Chavan, Yash Joshi, T Ajai Kumar, Triparna Majumdar, Abhinendra Kumar, Savita Patil, Renuka Munshi, Unnati Desai, Himanshu Kaushal, Annasaheb Suryawanshi, Manisha Dudhmal, Pranita Gawande, Rajlaxmi Jain, Ashwini Waghmare, Kaumudi Kalele, Pratiksha Vedpathak, Jyoti Yemul, Poonam Bodke, Tejashri Kore, A.L. Kakrani, Prachi Athavale, Poonam Suryawanshi, Sudhir Patsute, Vikram Padbidri, Pradip Awate, Priya Abraham
Journal: Journal of Infection (2022)
Incidence of Avoidable 30-Day Readmissions Following Hospitalization for Community-Acquired Pneumonia in France
Authors: Bastien Boussat, Fabiana Cazzorla, Marion Le Marechal, Patricia Pavese, Anne-Laure Mounayar, Elodie Sellier, Jacques Gaillat, Boubou Camara, Bruno Degano, Mylène Maillet, Xavier Courtois, Magali Bouisse, Arnaud Seigneurin, Patrice François
Journal: JAMA Network Open (2022)

<h3>Importance</h3> Rates of 30-day readmissions following hospitalization for pneumonia are used to publicly report on hospital performance and to set financial penalties for the worst-performing hospitals. However, the rate of avoidable readmission following hospitalization for pneumonia is undefined. <h3>Objective</h3> To assess how often 30-day readmissions following hospitalization for community-acquired pneumonia (CAP) are avoidable. <h3>Design, Setting, and Participants</h3> This cohort study analyzed the results of an independent review of readmissions following hospitalization for CAP within 30 days among patients discharged from 2 large hospitals in France in 2014. Structured clinical records including clinical information (ie, baseline characteristics, physical examination, laboratory findings, x-ray or computed tomography scan findings, discharge plan, and treatments) for both index and readmission stays were independently reviewed by 4 certified board physicians. All consecutive adult patients hospitalized in 2014 with a diagnosis of CAP in our 2 eligible hospitals were eligible. All analyses presented were performed in March 2021. <h3>Main Outcomes and Measures</h3> Avoidable readmission within 30 days of discharge from index hospitalization. The likelihood that a readmission was avoidable was quantified using latent class analysis based on the independent reviews. A readmission was considered avoidable if Bayes posterior probability exceeded 50%. <h3>Results</h3> The total analytical sample consisted of 1150 index hospital stays with a diagnosis of CAP, which included 651 (56.6%) male patients. The median (IQR) age for all patients was 77.8 (IQR, 62.7-86.4) years. Out of the 1150 index hospital stays, 98 patients (8.5%) died in hospital, and 108 (9.4%) unplanned readmissions were found. Overall, 15 readmissions had a posterior probability of avoidability exceeding 0.50 (13.9% of the 108 unplanned readmissions; 95% CI, 8.0%-21.9%). The median (IQR) delay between the hospital discharge index and readmission was considerably shorter when readmission was deemed avoidable (4 [6-21] days vs 12 [2-18] days;<i>P</i> = .02). <h3>Conclusions and Relevance</h3> Only a small number of readmissions following hospitalization for CAP were deemed avoidable, comprising less than 10% of all readmissions. Shorter time interval between hospitalization discharge and readmission was associated with avoidability.
Genetic variants underlying differences in facial morphology in East Asian and European populations
Authors: Manfei Zhang, Sijie Wu, Siyuan Du, Wei Qian, Jieyi Chen, Lu Qiao, Yajun Yang, Jingze Tan, Ziyu Yuan, Qianqian Peng, Yu Liu, Nicolas Navarro, Kun Tang, Andrés Ruiz-Linares, Jiucun Wang, Peter Claes, Li Jin, Jiarui Li, Sijia Wang
Journal: Nature Genetics (2022)
Antilogic, a new supervised machine learning software for the automatic interpretation of antibiotic susceptibility testing in clinical microbiology: proof-of-concept on three frequently isolated bacterial species
Authors: Andriamiharimamy Rajaonison, Stéphanie Le Page, Thomas Maurin, Hervé Chaudet, Didier Raoult, Sophie Alexandra Baron, Jean-Marc Rolain
Journal: Clinical Microbiology and Infection (2022)
Expanding Horizons for Treatment of Early-Stage Lung Cancer
Authors: Christine M. Lovly
Journal: New England Journal of Medicine (2022)

Lung cancer remains the leading cause of cancer-related death worldwide.1 Even in the context of early-stage disease, survival among patients with lung cancer lags behind that among patients with other common cancers, such as colon, breast, and prostate cancer. The likelihood of 5-year survival remains modest,2 with patients having both local or regional relapse and metastatic relapse. Although surgery with curative intent remains the foundation for management of early-stage lung cancer, these data speak to the urgent need for improvements in systemic control. With the advent of targeted therapies directed against mutant oncoproteins and immune-checkpoint inhibitors to promote host antitumor . . .
Use of Antenatal Corticosteroids for Risk of Preterm Birth—Is Timing Everything?
Authors: Andrea F. Duncan, Daniel T. Malleske, Nathalie L. Maitre
Journal: JAMA Pediatrics (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Aging Out of Childhood Insomnia? Not Some Kids
Authors: Anita Slomski
Journal: JAMA (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia
Authors: Byungho Lim, Dabin Yoo, Younghwa Chun, Areum Go, Kyung-Jin Cho, Daeun Choi, Myoung Eun Jung, Ha Young Lee, Rebecca J. Boohaker, Jin Soo Lee, DooYoung Jung, Gildon Choi
Journal: Blood Cancer Journal (2022)

The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia
TCTAP C-174 Successful Transcatheter Aortic Valve Replacement With SAPIEN 3 Valve in a Patient With Quadricuspid Aortic Stenosis
Authors: Tomoki Ochiai, Futoshi Yamanaka, Noriaki Moriyama, Koki Shishido, Shigeru Saito
Journal: Journal of the American College of Cardiology (2022)
Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia
Authors: Ángel Arenal, Pablo Ávila, Javier Jiménez-Candil, Luis Tercedor, David Calvo, Fernando Arribas, Javier Fernández-Portales, José Luis Merino, Antonio Hernández-Madrid, Francisco J Fernández-Avilés, Antonio Berruezo
Journal: Journal of the American College of Cardiology (2022)
Measurement of Midregional Pro-Atrial Natriuretic Peptide to Discover Atrial Fibrillation in Patients With Ischemic Stroke
Authors: Juliane Schweizer, Markus Arnold, Inke R. König, Antonela Bicvic, Laura P. Westphal, Valerie Schütz, Corinne Inauen, Natalie Scherrer, Andreas Luft, Marian Galovic, Carolina Ferreira Atuesta, Thomas Pokorny, Marcel Arnold, Urs Fischer, Leo H. Bonati, Gian Marco De Marchis, Timo Kahles, Krassen Nedeltchev, Carlo W. Cereda, Georg Kägi, Alejandro Bustamante, Joan Montaner, Georg Ntaios, Dimitrios Sagris, Christian Foerch, Katharina Spanaus, Arnold von Eckardstein, Mira Katan
Journal: Journal of the American College of Cardiology (2022)
Re: Zachary Klaassen, Emily Vertosick, Andrew J. Vickers, et al. Optimal Dissemination of Scientific Manuscripts via Social Media: A Prospective Trial Comparing Visual Abstracts Versus Key Figures in Consecutive Original Manuscripts. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.01.041
Authors: Benjamin Davies, Keith Kowalczyk
Journal: European Urology (2022)
Error in Supplement 2
Journal: JAMA Network Open (2022)

Csilla Várnai, PhD; Claire Palles, PhD; Roland Arnold, PhD; Helen M. Curley, PhD; Karin Purshouse, MBBS; Vinton W. T. Cheng, DPhil; Stephen Booth, MB, BChir; Naomi A. Campton, PhD; Graham P. Collins, MBBS; Daniel J. Hughes, MBBS; Austin G. Kulasekararaj, MD; Alvin J. X. Lee, PhD; Anna C. Olsson-Brown, MBChB; Archana Sharma-Oates, PhD; Mieke Van Hemelrijck, PhD; Lennard Y. W. Lee, DPhil; Rachel Kerr, MRCP; Gary Middleton, MD; Jean-Baptiste Cazier, PhD; UKCCMP Team; Sian Pugh; Pippa Corrie; Ahmed Bedair; Madeleine Hewish; Pauline Leonard; Jack Illingworth; Stephen Hibbs; Nicolaos Diamantis; Samah Massalha; Claire Fuller; Caroline Usbourne; Duncan Gilbert; Jennifer Davies; Tom Newsom-Davis; Rachel Sharkey; Rebecca Lee; Ann Tivey; Rohan Shotton; Clare Griffin; Laura Horsley; Simon Shamas; Joseph J Sacco; Madbuba Choudhury; Jillian Noble; Heather Shaw; Rachel Bolton; Ana Ferreira; Peter Hall; Paul Ramage; Jaishree Bhosle; Alison Massey; Michaela Hill; Leena Mukherjee; Aisha Ghaus; Sarah Derby; Sean Brown; Sarah Lowndes; Saorise Dolly; Beth Russell; Charlotte Moss; Daniel Muller; Annet Pillai; Shakeel Lowe; Lucy Cook; Christopher Scrase; Rema Jyothirmayi; Ruth Board; Stephanie Cornthwaite; Shefail Parikh; Emma Cattell; Nicola Cox; Abigail Gault; Sam Moody; Caroline Dobeson; Mark Baxter; Tom Roques; Alexander Pawsey; Roderick Oakes; Lucinda Melcher; Olivia Chan; Sarah Ayers; Helen Bowyer; Mohammed Althohami; Sajjan Mittal; Laura Feeney; Avinash Aujayeb; Omar Sheikh; Sangary Kathirgamakarthigeyan; Victoria Woodcock; Francesca Holt; Simon Wyatt; Oliver Topping; Michael Tilby; Madhumita Bhattacharyya; Emma Burke; Shawn Ellis; Joseph Chacko; Taslima Rabbi; Michael Rowe; Rebecca Sargent; Christina Thirlwell; Jack Gibson; Robert Goldstein; Mathew Fittall; Spyridon Gennatas; Alicia Okines; James Best; Tania Tillett; Emily Renninson; Simon Grumett; Craig Barrington; Ruth Pettengell; YingyYing Peng; Julia Chackathayil; Akinfemi Akingboye; Helen Hollis; Ik Shin Chin; Vartika Bisht; Simon Hartley; Christopher P Middleton; Anshita Goel; Emily Protheroe; Paingfan Naksukpaiboon; Iris Anil; Joel Michell; Jamie D'Costa; Anjui Wu; Diego Ottaviani; Gehan Soosaipillai; Myria Galazi; Neha Chopra; Sarah Benafif; Christopher CT Sng; Sophia YN Wong; Martin Scott-Brown; Ellen Copson; Timothy Robinson; Zoe Hudson; Fiona Smith; Ali-Abdulnabi Mohamed; Angelos Angelakas; Leoni Eastlake; Ashley Poon-King; Clair Brunner; Amy Kwan; Alec Maynard; Hayley Boyce; Emma Spurrell; Rahul Peck; Bartlomiej Kurec
Additively manufactured pure zinc porous scaffolds for critical-sized bone defects of rabbit femur
Authors: Dandan Xia, Yu Qin, Hui Guo, Peng Wen, Hong Lin, Maximilian Voshage, Johannes Henrich Schleifenbaum, Yan Cheng, Yufeng Zheng
Journal: Bioactive Materials (2022)

Additive manufacturing has received attention for the fabrication of medical implants that have customized and complicated structures. Biodegradable Zn metals are revolutionary materials for orthopedic implants. In this study, pure Zn porous scaffolds with diamond structures were fabricated using customized laser powder bed fusion (L-PBF) technology. First, the mechanical properties, corrosion behavior, and biocompatibility of the pure Zn porous scaffolds were characterized in vitro. The scaffolds were then implanted into the rabbit femur critical-size bone defect model for 24 weeks. The results showed that the pure Zn porous scaffolds had compressive strength and rigidity comparable to those of cancellous bone, as well as relatively suitable degradation rates for bone regeneration. A benign host response was observed using hematoxylin and eosin (HE) staining of the heart, liver, spleen, lungs, and kidneys. Moreover, the pure Zn porous scaffold showed good biocompatibility and osteogenic promotion ability in vivo. This study showed that pure Zn porous scaffolds with customized structures fabricated using L-PBF represent a promising biodegradable solution for treating large bone defects.
Response of Leptomeningeal Metastasis of Breast Cancer With a HER2/neu Activating Variant to Tucatinib: A Case Report
Authors: Fengting Yan, Kristine J. Rinn, Jonathon A. Kullnat, Aimee Y. Wu, Maura D. Ennett, Elizabeth L. Scott, Henry G. Kaplan
Journal: Journal of the National Comprehensive Cancer Network (2022)

Metastatic breast cancer demonstrates HER2/neu amplification approximately 15% of the time. However, HER2 mutations, which often stimulate tumor growth, occur in only 3% to 5% of patients, and are seen more frequently in metastatic versus primary tumors. They are more frequent in lobular carcinoma, including triple-negative lobular cancer. Many of these variants are resistant to trastuzumab and lapatinib. However, neratinib can be efficacious, and recent data suggest that antibody–drug conjugates (ADCs) such as ado-trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan may also be helpful. Laboratory and clinical data raise the possibility that simultaneous treatment with ADCs plus neratinib may be even more efficacious. Tucatinib, which has demonstrated significant activity in the central nervous system, has also been shown in vitro to be active against a number of these HER2 variants. This report describes a patient with metastatic estrogen receptor–positive, HER2 -nonamplified breast cancer with an activating HER2 mutation whose tumor became resistant to neratinib as well as capecitabine, but whose subsequent leptomeningeal disease had a dramatically successful response to tucatinib plus capecitabine. As the frequency of HER2 mutations increases during the evolution of metastatic breast cancer, it is important to obtain genomic evaluation on these tumors with either repeat tissue or liquid biopsy as they progress over time.
Risk of strong antibody decline in dialysis and transplant patients after SARS-CoV-2mRNA vaccination: Six months data from the observational Dia-Vacc study
Authors: Julian Stumpf, Jörg Schwöbel, Tom Lindner, Leona Anders, Torsten Siepmann, Claudia Karger, Jan Hüther, Heike Martin, Petra Müller, Robert Faulhaber-Walter, Torsten Langer, Holger Schirutschke, Thomas Stehr, Frank Meistring, Annegret Pietzonka, Kirsten Anding-Rost, Katja Escher, Frank Pistrosch, Jens Schewe, Harald Seidel, Kerstin Barnett, Thilo Pluntke, Simon Cerny, Alexander Paliege, Ingolf Bast, Anne Steglich, Florian Gembardt, Friederike Kessel, Hannah Kröger, Patrick Arndt, Jan Sradnick, Kerstin Frank, Anna Klimova, René Mauer, Xina Grählert, Torsten Tonn, Christian Hugo
Journal: The Lancet Regional Health - Europe (2022)
Rare ATG7 genetic variants predispose patients to severe fatty liver disease
Authors: Guido A. Baselli, Oveis Jamialahmadi, Serena Pelusi, Ester Ciociola, Francesco Malvestiti, Marco Saracino, Luigi Santoro, Alessandro Cherubini, Paola Dongiovanni, Marco Maggioni, Cristiana Bianco, Federica Tavaglione, Annalisa Cespiati, Rosellina M. Mancina, Roberta D’Ambrosio, Valentina Vaira, Salvatore Petta, Luca Miele, Umberto Vespasiani-Gentilucci, Alessandro Federico, Jussi Pihlajamaki, Elisabetta Bugianesi, Anna L. Fracanzani, Helen L. Reeves, Giorgio Soardo, Daniele Prati, Stefano Romeo, Luca VC. Valenti, Vittorio Borroni, Antonio Liguori, Luisa Ronzoni, Alessandro Cherubini, Luigi Santoro, Melissa Tomasi, Angela Lombardi, Mahnoosh Ostadreza, Elia Casirati, Ilaria Marini, Silvia Maier, Chiara Rosso, Gianluca Svegliati Baroni, Carlo Santaniello, Marcello Dallio
Journal: Journal of Hepatology (2022)

Non-alcoholic fatty liver disease (NAFLD) is the leading cause of liver disorders and has a strong heritable component. The aim of this study was to identify new loci that contribute to severe NAFLD by examining rare variants.
TCTAP A-032 One Year Patency of Biorestorative Polymeric Coronary Artery Bypass Grafts in an Ovine Model: Serial Assessment of Quantitative Coronary Angiography and Flow Ratio
Authors: Masafumi Ono, Xinlei Wu, Mohammed S. El-Kurdi, Jochen Reinöhl, Renu Virmani, Martijn Cox, Yoshinobu Onuma, Patrick W. Serruys
Journal: Journal of the American College of Cardiology (2022)
Treatment and outcomes of patients with light chain amyloidosis who received a second line of therapy post autologous stem cell transplantation
Authors: Abdullah S. Al Saleh, Mohammad S. Ebraheem, M. Hasib Sidiqi, Angela Dispenzieri, Eli Muchtar, Francis K. Buadi, Rahma Warsame, Martha Q. Lacy, David Dingli, Wilson I. Gonsalves, Taxiarchis V. Kourelis, William J. Hogan, Suzanne R. Hayman, Prashant Kapoor, Shaji K. Kumar, Morie A. Gertz
Journal: Blood Cancer Journal (2022)

We retrospectively reviewed 292 patients who received a second line of therapy post ASCT for their light chain amyloidosis. Most patients (40%) were treated with an alkylator + PI ± dex or PI ± dex followed by an alkylator + 2nd-gen IMiD ± dex or 2nd-gen IMiD ± dex (26%), an alkylator ± steroid or steroid monotherapy (19%), a 2nd-gen IMiD + PI ± dex (6%), an alkylator + thalidomide ± dex (5%), or daratumumab-based therapy (4%). The rate of CR or VGPR was 70% among the daratumumab-based group, 62% in the alkylator + PI ± dex or PI ± dex group, 55% in the alkylator + 2nd-gen IMiD ± dex or 2nd-gen IMiD ± dex group, 47% in the 2nd-gen IMiD + PI ± dex group, 24% in the alkylator ± steroid or steroid monotherapy group, and 18% in the alkylator + thalidomide ± dex group. The median OS was NR for the 2nd-gen IMiD + PI ± dex group and the daratumumab group, 130.4 months in the alkylator + 2nd-gen IMiD ± dex or 2nd-gen IMiD ± dex group, 100 months for the alkylator + PI ± dex or PI ± dex group, 36 months for the alkylator ± steroid or steroid monotherapy group, and 21 months for the alkylator + thalidomide ± dex group (P < 0.0001). The median OS was 100 months in patients who received melphalan 200 mg/m2 compared to 41 months in the 140 mg/m2 group (P < 0.0001). In conclusion, patients receiving novel therapy post ASCT and melphalan conditioning dosing at 200 mg/m2 at diagnosis had better outcomes.
Image Consent and the Development of Image-Based Artificial Intelligence—Reply
Authors: Roxana Daneshjou, Veronica Rotemberg
Journal: JAMA Dermatology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal